A Phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer

BACKGROUND: Activating mutations in PIK3CA promote resistance to HER2-targeted therapy in breast cancer, however inhibition of PI3K alone leads to escape via feedback upregulation of HER3. Combined inhibition of HER2, HER3 and PI3K overcomes this mechanism preclinically. METHODS: This phase I study...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Cancer Res
Main Authors: Jhaveri, Komal, Drago, Joshua Z., Shah, Payal Deepak, Wang, Rui, Pareja, Fresia, Ratzon, Fanni, Iasonos, Alexia, Patil, Sujata, Rosen, Neal, Fornier, Monica N., Sklarin, Nancy T., Chandarlapaty, Sarat, Modi, Shanu
Format: Artigo
Sprog:Inglês
Udgivet: 2021
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8282678/
https://ncbi.nlm.nih.gov/pubmed/33947692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-21-0047
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker